Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5
- PMID: 28423649
- PMCID: PMC5438702
- DOI: 10.18632/oncotarget.15957
Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5
Abstract
Novel agents are still urgently expected for therapy of chronic myeloid leukemia (CML). The in vitro anti-leukemia activity of Stellettin B (Stel B), a triterpenoid we isolated from marine sponge Jaspis stellifera, on human CML K562 and KU812 cells was recently investigated. Stel B inhibited K562 and KU812 cell proliferation with IC50 as 0.035 μM and 0.95 μM respectively. While no obvious cell cycle arrest was observed, apoptosis was induced in K562 cells after Stel B treatment. The Stel B-induced apoptosis might be in mitochondrial pathway, with increase of Bad and Bax, decrease of Bcl-2 and activation of caspase-9. In addition, dose-dependent increase of reactive oxygen species (ROS) and loss of mitochondrial membrane potential (MMP) occurred. Meanwhile, Stel B inhibited phosphorylation of Stat5, expression of 4 PI3K catalytic isoforms, and phosphorylation of the downstream effectors including PDK1 and Akt, suggesting that inhibition against Stat5 and PI3K might be involved in the apoptosis-inducing effect. Combination of Stel B with Imatinib with ratio as IC50 Stel B : 5×IC50 Imatinib led to synergistic effect. Stel B might become a promising candidate for CML therapy alone or together with Imatinib.
Keywords: K562; PI3K; apoptosis; combination; stellettin B.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway.Sci Rep. 2016 May 31;6:27071. doi: 10.1038/srep27071. Sci Rep. 2016. PMID: 27243769 Free PMC article.
-
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.Drug Des Devel Ther. 2017 Apr 3;11:1115-1126. doi: 10.2147/DDDT.S132092. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28435223 Free PMC article.
-
Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.Int J Mol Med. 2018 Jan;41(1):455-463. doi: 10.3892/ijmm.2017.3205. Epub 2017 Oct 20. Int J Mol Med. 2018. PMID: 29115375
-
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442. Haematologica. 2014. PMID: 24598853 Free PMC article. Review.
-
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia.Int J Mol Sci. 2019 Jan 18;20(2):412. doi: 10.3390/ijms20020412. Int J Mol Sci. 2019. PMID: 30669372 Free PMC article. Review.
Cited by
-
Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition.Mar Drugs. 2024 Mar 23;22(4):143. doi: 10.3390/md22040143. Mar Drugs. 2024. PMID: 38667760 Free PMC article. Review.
-
Deep-Sea Sponges and Corals off the Western Coast of Florida-Intracellular Mechanisms of Action of Bioactive Compounds and Technological Advances Supporting the Drug Discovery Pipeline.Mar Drugs. 2023 Nov 28;21(12):615. doi: 10.3390/md21120615. Mar Drugs. 2023. PMID: 38132936 Free PMC article. Review.
-
Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells.Oncol Rep. 2023 Sep;50(3):170. doi: 10.3892/or.2023.8607. Epub 2023 Jul 28. Oncol Rep. 2023. PMID: 37503758 Free PMC article.
-
Stellettin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade.Mar Drugs. 2023 Jan 21;21(2):73. doi: 10.3390/md21020073. Mar Drugs. 2023. PMID: 36827114 Free PMC article.
-
Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics.Front Pharmacol. 2022 Aug 10;13:842376. doi: 10.3389/fphar.2022.842376. eCollection 2022. Front Pharmacol. 2022. PMID: 36034846 Free PMC article. Review.
References
-
- Puissant A, Colosetti P, Robert G, Cassuto JP, Raynaud S, Auberger P. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. Leukemia. 2010(24):115–124. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous